JP2022545167A5 - - Google Patents

Info

Publication number
JP2022545167A5
JP2022545167A5 JP2022505440A JP2022505440A JP2022545167A5 JP 2022545167 A5 JP2022545167 A5 JP 2022545167A5 JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022545167 A5 JP2022545167 A5 JP 2022545167A5
Authority
JP
Japan
Prior art keywords
tgf
receptor
chimeric cytokine
cytokine receptor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022505440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545167A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048402 external-priority patent/WO2021041806A1/en
Publication of JP2022545167A publication Critical patent/JP2022545167A/ja
Publication of JP2022545167A5 publication Critical patent/JP2022545167A5/ja
Pending legal-status Critical Current

Links

JP2022505440A 2019-08-30 2020-08-28 Tgfベータ結合ドメインを含むキメラサイトカイン受容体 Pending JP2022545167A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894658P 2019-08-30 2019-08-30
US62/894,658 2019-08-30
US202063053322P 2020-07-17 2020-07-17
US63/053,322 2020-07-17
PCT/US2020/048402 WO2021041806A1 (en) 2019-08-30 2020-08-28 Chimeric cytokine receptors comprising tgf beta binding domains

Publications (2)

Publication Number Publication Date
JP2022545167A JP2022545167A (ja) 2022-10-26
JP2022545167A5 true JP2022545167A5 (cg-RX-API-DMAC7.html) 2023-09-01

Family

ID=72521701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505440A Pending JP2022545167A (ja) 2019-08-30 2020-08-28 Tgfベータ結合ドメインを含むキメラサイトカイン受容体

Country Status (11)

Country Link
US (1) US12528856B2 (cg-RX-API-DMAC7.html)
EP (1) EP4021582A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022545167A (cg-RX-API-DMAC7.html)
KR (1) KR20220052919A (cg-RX-API-DMAC7.html)
CN (1) CN114341193A (cg-RX-API-DMAC7.html)
AU (1) AU2020336131B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003553A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145614A1 (cg-RX-API-DMAC7.html)
IL (1) IL290960A (cg-RX-API-DMAC7.html)
MX (1) MX2022002297A (cg-RX-API-DMAC7.html)
WO (1) WO2021041806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL285941B1 (en) * 2019-03-01 2026-08-01 Allogene Therapeutics Inc Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN
WO2022020456A2 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
CN117120075A (zh) * 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽
CA3217252A1 (en) * 2021-04-19 2022-10-27 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and uses thereof in cellular therapies
CA3230292A1 (en) 2021-08-27 2023-03-02 Theranotics Co., Ltd. Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof
CN115873802A (zh) * 2021-09-29 2023-03-31 亘喜生物科技(上海)有限公司 嵌合抗原受体免疫细胞及其制法和应用
US20250041336A1 (en) * 2021-09-29 2025-02-06 Vita Therapeutics, Inc. Methods and compositions for treating cancer with engineered cells
JP2024539013A (ja) * 2021-10-20 2024-10-28 フェイト セラピューティクス,インコーポレイティド 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用
GB202117298D0 (en) * 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
EP4479068A4 (en) * 2022-02-18 2026-01-07 Univ California ENHANCED MULTIPLICATION AND FUNCTION OF PRIMARY HUMAN NK CELLS BY A CHIMERICAL CYTOKINE RECEPTOR
EP4499680A1 (en) * 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
GB202301421D0 (en) * 2023-02-01 2023-03-15 Univ Oslo Hf Switch receptor for use in adoptive cell therapy
CN116284449B (zh) * 2023-02-27 2024-11-19 深圳市先康达生命科学有限公司 增强型TGF-βR嵌合受体及其应用
EP4724086A1 (en) * 2023-06-06 2026-04-15 F. Hoffmann-La Roche AG Switch receptors
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114825A0 (en) 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1998002558A2 (en) 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
EP1033374B1 (en) 1997-11-26 2012-08-01 Chugai Seiyaku Kabushiki Kaisha Signal sequence trapping method
WO2007075899A2 (en) 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
WO2011069004A1 (en) 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2014172584A1 (en) * 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
AU2015330017A1 (en) 2014-10-07 2017-04-27 Cellectis Method for modulating car-induced immune cells activity
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
DK3227339T3 (da) 2014-12-05 2022-01-10 Memorial Sloan Kettering Cancer Center Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
EP3234145B1 (en) 2014-12-15 2019-06-05 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
WO2016168612A1 (en) 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
EP3368571B1 (en) * 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2018161064A1 (en) 2017-03-03 2018-09-07 F1 Oncology, Inc. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
WO2019055946A1 (en) * 2017-09-18 2019-03-21 F1 Oncology, Inc. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF
CN106399255B (zh) 2016-04-13 2019-10-18 阿思科力(苏州)生物科技有限公司 Pd-1 car-t细胞及其制备方法和应用
CN118546961A (zh) * 2016-08-26 2024-08-27 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
US11654158B2 (en) * 2016-11-17 2023-05-23 2Seventy Bio, Inc. TGFBeta signal convertor
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201702617D0 (en) 2017-02-17 2017-04-05 Autolus Ltd Receptor
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
AU2019227979B2 (en) 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
CN112533942A (zh) 2018-06-01 2021-03-19 华盛顿大学 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
CN112368298A (zh) 2018-06-22 2021-02-12 凯德药业股份有限公司 嵌合跨膜蛋白及其用途
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
IL328846A (en) 2019-03-01 2026-08-01 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases
IL285941B1 (en) * 2019-03-01 2026-08-01 Allogene Therapeutics Inc Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN

Similar Documents

Publication Publication Date Title
JP7179041B2 (ja) 三官能性t細胞-抗原カプラ及び方法並びにこれらの使用
AU2020336131B2 (en) Chimeric cytokine receptors comprising TGF beta binding domains
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
CN110616191B (zh) 共刺激配体联合的car t疗法
JP2022537824A5 (cg-RX-API-DMAC7.html)
JP2023552998A5 (cg-RX-API-DMAC7.html)
CN110511912B (zh) 免疫细胞的功能调节
JP7227630B2 (ja) Y182t突然変異を有するt細胞-抗原カプラおよびその方法ならびに使用
JP2017504601A5 (cg-RX-API-DMAC7.html)
JP2022512913A5 (cg-RX-API-DMAC7.html)
JP7404279B2 (ja) 様々な構築物最適化を備えたt細胞抗原カプラ
JP2024510900A5 (cg-RX-API-DMAC7.html)
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
CN108138148A (zh) T细胞的激活和扩增
CN111019905A (zh) Car修饰细胞及其在制备自身免疫性疾病药物中的应用
JP2023548974A (ja) T細胞抗原カプラを含む細胞及びその使用
JP2022525925A5 (cg-RX-API-DMAC7.html)
CN111826353A (zh) 调节t细胞功能和反应的方法
CN115873801A (zh) 工程化免疫细胞及其用途
CN119661725A (zh) Il5ra细胞表面标记物
JP2025506515A5 (cg-RX-API-DMAC7.html)
CN112251452A (zh) Til/tcr-t细胞治疗平台
WO2024011335A1 (zh) 经修饰的免疫细胞
HK40054580A (en) Trifunctional t cell-antigen coupler and methods and uses thereof
CN119998452A (zh) 编码car的核酸分子和包含其的载体、car、包含car的免疫细胞和包含该细胞的药物组合物及包含car的免疫细胞的制备方法